Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model
| Autor: | Laura K. Najvar, John R. Graybill, Leila Zarif, Rosie Bocanegra, David S. Perlin, Raphael J. Mannino |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Antifungal Agents
animal structures animal diseases Antifungal drug Spleen Microbiology Mice Minimum inhibitory concentration Amphotericin B Candida albicans parasitic diseases medicine Animals Humans Experimental Therapeutics Pharmacology (medical) Pharmacology Liposome biology urogenital system Candidiasis technology industry and agriculture biology.organism_classification medicine.disease Corpus albicans Hemolysis Infectious Diseases medicine.anatomical_structure medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 44:1463-1469 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | Cochleates are lipid-based supramolecular assemblies composed of natural products, negatively charged phospholipid, and a divalent cation. Cochleates can encapsulate amphotericin B (AmB), an important antifungal drug. AmB cochleates (CAMB) have a unique shape and the ability to target AmB to fungi. The minimal inhibitory concentration and the minimum lethal concentration against Candida albicans are similar to that for desoxycholate AmB (DAMB; Fungizone). In vitro, CAMB induced no hemolysis of human red blood cells at concentrations of as high as 500 μg of AmB/ml, and DAMB was highly hemolytic at 10 μg of AmB/ml. CAMB protect ICR mice infected with C. albicans when the agent is administered intraperitoneally at doses of as low as 0.1 mg/kg/day. In a tissue burden study, CAMB, DAMB, and AmBisome (liposomal AmB; LAMB) were effective in the kidneys, but in the spleen CAMB was more potent than DAMB at 1 mg/kg/day and was equivalent to LAMB at 10 mg/kg/day. In summary, CAMB are highly effective in treating murine candidiasis and compare well with AmBisome and AmB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|